With years of experience in the field of anti-virus biomolecular discovery, Creative Biolabs has become a world-leading service provider skilled in providing the first-in-class service for the discovery of antibody and peptide targeting EV71. Based on our Anti-Virus Biomolecular Discovery platform, we guarantee high-quality services in a cost- and time-efficient manner.
Hand-foot-mouth diseases (HFMDs) are mainly caused by Coxsackie virus (CV) and Enterovirus 71 (EV71) infections and have become serious public health problems in Southeast Asia. EV71 epidemics have always been associated with fatalities and neurological complications in children. Enterovirus 71 (EV71) is a non-enveloped single strand RNA virus of the Picornaviridae family, genus Enterovirus. EV71 viral capsid is composed of four structural proteins: VP1, VP2, VP3 and VP4. The VP1, VP2 and VP3 proteins are exposed on the virion surface and are responsible for host-receptor binding and immune responses. EV71 is classified into 3 genotypes A, B, and C, and further divided into B1-B5 and C1-C5 sub-genotypes. Therefore, an effective HFMD vaccine should elicit strong cross-neutralizing antibody responses against different genotypes of EV71. Several EV71 vaccines are presently being developed and evaluated in human clinical trials.
Immunization with virus-like particles (VLPs) has been proven a successful strategy to prevent various infectious diseases. For the sake of viral nucleic acids infection leading to potential side effects, VLPs which are empty particles composed of merely viral capsid proteins can serve as a more valuable tool for clinic trial and treatment in the future. EV71 VLPs have been proved that formulated with CFA could elicit virus neutralizing antibody responses with a high titer in mice and protected newborn mice against lethal EV71 challenges by passive immunization. These mouse antisera could neutralize different EV71 genotypes (C2, B4, C4, B5 and C5). Furthermore, the VP1 and VP2 proteins are the key targets as they contain a number of important neutralization sites. Several linear immunodominant neutralization epitopes VP1-43, VP1-49 and VP2-28 that respectively correspond to residues 211-225, 240-255 of VP1 and residues 136-150 of VP2 have also been selected to develop therapeutics against EV71.
Fig.1 Structural comparison of the protomers and individual capsid proteins of the CVA6 VLP, EV71 VLP, and CVA16 135S particle (Chen et al. 2017).
With years of experience in the field of antibody development, Creative Biolabs has successfully developed an advanced AntInfect™ Platform, which is optimal for therapeutic/diagnosis antibody generation. We are highly feasible with all immunization schemes, and our seasoned scientists can help you choose the suitable option. Combined with our stable and mature phage display technology, we can also assist in peptide inhibitors development. Please contact us for more information and a detailed quote.
References:
